Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation
Key facts
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 25 people, planned
- Started
- 23 Sept 2022
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- ClearFit implant
- transcranial ultrasonography through sonolucent cranioplasty
- Record updated
- 5 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Presence of spontaneous supratentorial ICH ≥20 mL
- Age ≥18 years
- National Institute of Health Stroke Scale (NIHSS) score ≥6
- GCS score 5-15 at presentation
- Undergoing minimally invasive intracerebral hemorrhage evacuation with sonolucent cranioplasty or hemicraniectomy with sonolucent cranioplasty
Who cannot take part
- Active drug or alcohol abuse that, in the opinion of the site investigator, would interfere with adherence to study enrolments
- History of osteomyelitis
- History of skull neoplasm
- History of comminuted skull fractures
- Infratentorial hemorrhage
- Evidence of active infection indicated by fever ≥ 100.7F and/or open draining wound at the time of enrolment
- Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 1 year
- Coagulopathy defined as INR > 1.4, elevated aPTT, or concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset; known hereditary or acquired hemorrhagic diathesis; coagulation factor deficiency; platelet count < 100x103cells/mm3, or known platelet dysfunction
- Secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct
- Midbrain extension/involvement
- Inability to obtain consent from patient or appropriate surrogate (for patients without capacity)
- Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up appointment schedule
- Pre-existing DNR/DNI status
This trial is currently available in United States.
- Mount Sinai Health SystemNew York, United StatesContact: Christopher P. Kellner, MDTaking people
About the trial
What the trial wants to find out
Postoperative rebleeding is a major limitation of surgical evacuation for intracerebral hemorrhage (ICH). While computed tomography (CT) is the standard of care for postoperative hematoma cavity monitoring, CT requires significant physical and financial costs. Studies have demonstrated varying degrees of efficacy when using transcranial ultrasound to measure ICH volume. Recently, synthetic implants for cranioplasty have been shown to be safe and sonolucent. This study aims to evaluate the ability of transcranial ultrasound with sonolucent cranioplasty (TUSC) to detect and quantify bleeding in postoperative ICH patients.
The group in the trial
- transcranial ultrasonography through sonolucent cranioplastyTreatment being tested
All surgical procedures and implants in this protocol are standard of care.
Treatment: ClearFit implant and transcranial ultrasonography through sonolucent cranioplasty
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 May 2026